Technetium (99mTc) medronic acid

Tc-99m medronic acid skeletal

Radiopharmaceutical used in bone imaging

Technetium (99mTc) medronic acid
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Intravenous
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Technetium (99mTc) medronic acid is a radiopharmaceutical used primarily in nuclear medicine for bone imaging. It is a compound that combines technetium-99m (99mTc), a widely used radioisotope, with medronic acid, a phosphonate compound that targets bone tissue.

Mechanism of Action

Technetium (99mTc) medronic acid works by binding to the hydroxyapatite crystals in bone. The technetium-99m emits gamma radiation, which can be detected by a gamma camera. This allows for the visualization of bone structure and the identification of abnormalities such as bone metastases, fractures, and osteomyelitis.

Clinical Use

Technetium (99mTc) medronic acid is used in bone scintigraphy, a diagnostic imaging technique. It is particularly useful for detecting bone metastases in patients with cancer, evaluating unexplained bone pain, and diagnosing osteomyelitis.

Administration

The compound is administered intravenously. After injection, it typically takes about 2-4 hours for optimal imaging, as the radiopharmaceutical accumulates in the bone tissue.

Safety and Side Effects

Technetium (99mTc) medronic acid is generally well-tolerated. However, potential side effects include allergic reactions, injection site reactions, and, rarely, radiation exposure risks. It is contraindicated in patients with known hypersensitivity to any component of the formulation.

Related Pages

• Technetium-99m
• Radiopharmaceutical
• Bone scintigraphy
• Nuclear medicine
• Bone metastasis
• Osteomyelitis

Categories

   This article is a medical stub. You can help WikiMD by expanding it!